Discgenics Receives "Notice of Issuance" on its First U.S. Patent Application

SALT LAKE CITY, July 25, 2012 /PRNewswire/ --  Discgenics, Inc. (Discgenics) announced today the receipt of a "Notice of Issuance" from the United States Patent and Trademark Office (USPTO) on it first patent, "Compositions of Adult Disc Stem Cells and Methods for the Treatment of Degenerative Disc Disease".

Discgenics' CEO, Flagg Flanagan said, "We are excited to have obtained our first patent that provides Discgenics with coverage on our proprietary culture system that includes a resulting composition comprising a disc stem cell population from a nucleus pulposus source that forms Discospheres™ when grown following the Discgenics culture system method." Discgenics has a series of additional patent applications that include more recent scientific discoveries, and will be expanded to cover the specific devices that will utilize the Discosphere technology.

About Discgenics, Inc.

Discgenics is a privately funded spinal therapeutics company that is utilizing adult human disc stem cells within a tissue engineering approach to treat patients debilitated by Degenerative Disc Disease. News and other information on the company are available at: http://www.discgenics.com.

Media Contact: Flagg Flanagan
Chief Executive Officer
801-410-0703
[email protected]

SOURCE Discgenics, Inc.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.